Andrew Davies

University of Southampton

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (13)

Laura Hilton

Adjunct Professor

Simon Fraser University

CANADA

View details

Sarah Pirrie

University of Birmingham

UNITED KINGDOM

View details

Daniel James Hodson

UNITED KINGDOM

View details

Christoph Mamot

Head of the division

Kantonsspital Aarau AG

SWITZERLAND

View details

Jude Fitzgibbon

Professor in Personalised Cancer Medicine

Queen Mary University of London

UNITED KINGDOM

View details

Arash Ash Alizadeh

Professor of Medicine

Stanford University School of Medicine

UNITED STATES

View details

Peter Johnson

University of Southampton

UNITED KINGDOM

View details

Reuben M. Tooze

University of Leeds

UNITED KINGDOM

View details

Andrea Kuhnl

King's College Hospital

UNITED KINGDOM

View details

Richard Rosenquist

Karolinska Institutet

SWEDEN

View details

Laurence de Leval

Director of the Institute of Pathology / Professor of Pathology

Lausanne University Hospital

SWITZERLAND

View details

Elias Campo

University of Barcelona

SPAIN

View details

David Westhead

Prof

University of Leeds

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrew Davies

Research Interests

Explore related searches

Contact this professor

Articles (10)

The high-grade B-cell lymphomas: double hit and more

Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up

Genomic profiling for clinical decision making in lymphoid neoplasms.

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

DLBCL outcomes: much ventured, much GAINED

Precision Medicine in DLBCL: Are We There Yet?

Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial

A phase 2 open-label study of carboplatin in combination with gemcitabine as a dose-dense schedule in patients with locally advanced or metastatic breast cancer that are resistant to anthracyclines and taxanes

Collaborators (13)

Laura Hilton

Sarah Pirrie

Daniel James Hodson

Christoph Mamot

Jude Fitzgibbon

Arash Ash Alizadeh

Peter Johnson

Reuben M. Tooze

Andrea Kuhnl

Richard Rosenquist

Laurence de Leval

Elias Campo

David Westhead

Make your next move.